Current trends in the management of parkinsons diseases
Management of parkinson’s disease
Matteo Pastorino - Remote daily activity of parkinson’s disease patients the akinesia assessment
R E V I E W
Pharmacology by category
Guide to DBS Stimulation Therapy
CL-1 Parkinson’s Disease Dementia (PDD) A Clinical Perspective Howard Feldman, MDCM, FRCP (C) Professor and Head Division of Neurology Director-Clinic.
Pharmacologic treatment of Parkinson disease: Dr behnaz ansari.
Abstract Parkinson's disease (PD) is a well known disease estimated to affect 2% of people above age 60. It is a progressively debilitating disease affecting.
Towards end-user centered outcome measurement: An example from Parkinson’s disease Peter Hagell, RN PhD Professor of Neurological Caring Science The PRO-CARE.
Movement Disorders Mary Quiceno, M.D. Neurology. Hypokinetic & Hyperkinetic Movement Disorders Parkinson’s disease Parkinson’s Plus Syndromes –PSP.
Bracco, F., Battaglia A., Chouza C. et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year,